173 related articles for article (PubMed ID: 29141663)
1. Quality assurance of the SCOPE 1 trial in oesophageal radiotherapy.
Wills L; Maggs R; Lewis G; Jones G; Nixon L; Staffurth J; Crosby T;
Radiat Oncol; 2017 Nov; 12(1):179. PubMed ID: 29141663
[TBL] [Abstract][Full Text] [Related]
2. Is pre-trial quality assurance necessary? Experiences of the CONVERT Phase III randomized trial for good performance status patients with limited-stage small-cell lung cancer.
Groom N; Wilson E; Lyn E; Faivre-Finn C
Br J Radiol; 2014 May; 87(1037):20130653. PubMed ID: 24620839
[TBL] [Abstract][Full Text] [Related]
3. Driving developments in UK oesophageal radiotherapy through the SCOPE trials.
Gwynne S; Higgins E; Poon King A; Radhakrishna G; Wills L; Mukherjee S; Hawkins M; Jones G; Staffurth J; Crosby T
Radiat Oncol; 2019 Feb; 14(1):26. PubMed ID: 30717810
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy Quality Assurance for the CHHiP Trial: Conventional Versus Hypofractionated High-Dose Intensity-Modulated Radiotherapy in Prostate Cancer.
Naismith O; Mayles H; Bidmead M; Clark CH; Gulliford S; Hassan S; Khoo V; Roberts K; South C; Hall E; Dearnaley D;
Clin Oncol (R Coll Radiol); 2019 Sep; 31(9):611-620. PubMed ID: 31201110
[TBL] [Abstract][Full Text] [Related]
5. Pre-trial quality assurance processes for an intensity-modulated radiation therapy (IMRT) trial: PARSPORT, a UK multicentre Phase III trial comparing conventional radiotherapy and parotid-sparing IMRT for locally advanced head and neck cancer.
Clark CH; Miles EA; Urbano MT; Bhide SA; Bidmead AM; Harrington KJ; Nutting CM;
Br J Radiol; 2009 Jul; 82(979):585-94. PubMed ID: 19332518
[TBL] [Abstract][Full Text] [Related]
6. Technical quality assurance during the TROG 03.04 RADAR prostate radiotherapy trial: are the results reflected in observed toxicity rates?
Ebert MA; Bulsara M; Haworth A; Kearvell R; Richardson S; Kennedy A; Spry NA; Bydder SA; Joseph DJ; Denham JW
J Med Imaging Radiat Oncol; 2015 Feb; 59(1):99-108. PubMed ID: 25082363
[TBL] [Abstract][Full Text] [Related]
7. Questionnaire based quality assurance for the RT01 trial of dose escalation in conformal radiotherapy for prostate cancer (ISRCTN 47772397).
Mayles WP; Moore AR; Aird EG; Bidmead AM; Dearnaley DP; Griffiths SE; Warrington AP;
Radiother Oncol; 2004 Nov; 73(2):199-207. PubMed ID: 15622611
[TBL] [Abstract][Full Text] [Related]
8. Quality assurance analysis of participating centres' protocol compliance to a UK multicentre hypofractionated breast (FAST) trial.
Tsang Y; Venables K; Yarnold J;
Br J Radiol; 2012 Sep; 85(1017):e647-53. PubMed ID: 22294704
[TBL] [Abstract][Full Text] [Related]
9. Quality Assurance of Dose-Escalated Radiation Therapy in a Randomized Trial for Locally Advanced Oesophageal cancer.
Boustani J; Rivin Del Campo E; Blanc J; Peiffert D; Benezery K; Pereira R; Rio E; Le Prisé E; Créhange G; Huguet F
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):329-337. PubMed ID: 31299242
[TBL] [Abstract][Full Text] [Related]
10. The TRENDY multi-center randomized trial on hepatocellular carcinoma - Trial QA including automated treatment planning and benchmark-case results.
Habraken SJM; Sharfo AWM; Buijsen J; Verbakel WFAR; Haasbeek CJA; Öllers MC; Westerveld H; van Wieringen N; Reerink O; Seravalli E; Braam PM; Wendling M; Lacornerie T; Mirabel X; Weytjens R; Depuydt L; Tanadini-Lang S; Riesterer O; Haustermans K; Depuydt T; Dwarkasing RS; Willemssen FEJA; Heijmen BJM; Méndez Romero A
Radiother Oncol; 2017 Dec; 125(3):507-513. PubMed ID: 29050954
[TBL] [Abstract][Full Text] [Related]
11. The effect of planning algorithms in oesophageal radiotherapy in the context of the SCOPE 1 trial.
Wills L; Millin A; Paterson J; Crosby T; Staffurth J
Radiother Oncol; 2009 Dec; 93(3):462-7. PubMed ID: 19782420
[TBL] [Abstract][Full Text] [Related]
12. Use of EORTC target definition guidelines for dose-intensified salvage radiation therapy for recurrent prostate cancer: results of the quality assurance program of the randomized trial SAKK 09/10.
Sassowsky M; Gut P; Hölscher T; Hildebrandt G; Müller AC; Najafi Y; Kohler G; Kranzbühler H; Guckenberger M; Zwahlen DR; Azinwi NC; Plasswilm L; Takacs I; Reuter C; Sumila M; Manser P; Ost P; Böhmer D; Pilop C; Aebersold DM; Ghadjar P
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):534-41. PubMed ID: 23972722
[TBL] [Abstract][Full Text] [Related]
13. Contour variation is a primary source of error when delivering post prostatectomy radiotherapy: Results of the Trans-Tasman Radiation Oncology Group 08.03 Radiotherapy Adjuvant Versus Early Salvage (RAVES) benchmarking exercise.
Cloak K; Jameson MG; Paneghel A; Wiltshire K; Kneebone A; Pearse M; Sidhom M; Tang C; Fraser-Browne C; Holloway LC; Haworth A
J Med Imaging Radiat Oncol; 2019 Jun; 63(3):390-398. PubMed ID: 30950223
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy quality assurance for mesorectum treatment planning within the multi-center phase II STAR-TReC trial: Dutch results.
van den Ende RPJ; Peters FP; Harderwijk E; Rütten H; Bouwmans L; Berbee M; Canters RAM; Stoian G; Compagner K; Rozema T; de Smet M; Intven MPW; Tijssen RHN; Theuws J; van Haaren P; van Triest B; Eekhout D; Marijnen CAM; van der Heide UA; Kerkhof EM
Radiat Oncol; 2020 Feb; 15(1):41. PubMed ID: 32070386
[TBL] [Abstract][Full Text] [Related]
15. Target volume definition in conformal radiotherapy for prostate cancer: quality assurance in the MRC RT-01 trial.
Seddon B; Bidmead M; Wilson J; Khoo V; Dearnaley D
Radiother Oncol; 2000 Jul; 56(1):73-83. PubMed ID: 10869758
[TBL] [Abstract][Full Text] [Related]
16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
17. Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer.
Sydes MR; Stephens RJ; Moore AR; Aird EG; Bidmead AM; Fallowfield LJ; Graham J; Griffiths S; Mayles WP; McGuire A; Stanley S; Warrington AP; Dearnaley DP;
Radiother Oncol; 2004 Aug; 72(2):199-211. PubMed ID: 15297138
[TBL] [Abstract][Full Text] [Related]
18. Analysis of EORTC-1219-DAHANCA-29 trial plans demonstrates the potential of knowledge-based planning to provide patient-specific treatment plan quality assurance.
Tol JP; Dahele M; Gregoire V; Overgaard J; Slotman BJ; Verbakel WFAR
Radiother Oncol; 2019 Jan; 130():75-81. PubMed ID: 30348462
[TBL] [Abstract][Full Text] [Related]
19. Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer.
Hardcastle N; Cook O; Ray X; Moore A; Moore KL; Pryor D; Rossi A; Foroudi F; Kron T; Siva S
Radiat Oncol; 2021 Aug; 16(1):142. PubMed ID: 34344402
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
